# Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension

> **NCT03309592** · PHASE4 · WITHDRAWN · sponsor: **Ochsner Health System**

## Conditions studied

- Portopulmonary Hypertension
- Pulmonary Hypertension
- Cirrhosis, Liver

## Interventions

- **DRUG:** Ambrisentan Pill
- **DRUG:** Tadalafil Pill

## Key facts

- **NCT ID:** NCT03309592
- **Lead sponsor:** Ochsner Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-10-12
- **Primary completion:** 2018-11-01
- **Final completion:** 2018-11-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of eligible participants and failure to meeting study enrollment.
- **Last updated:** 2018-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03309592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03309592, "Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03309592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*